Evidence map›Paper›PMID 34876213›Full record

SynthesisStem cell research & therapy2021

Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials.

Armin Attar, Fateme Bahmanzadegan Jahromi, Shahin Kavousi, Ahmad Monabati, Asma Kazemi

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Stem cell research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 8 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 8 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. The Use of Hematopoietic Stem Cells for Heart Failure: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Armin AttarDepartment of Cardiovascular Medicine, TAHA Clinical Trial Group, School of Medicine, Shiraz University of Medical Sciences, Zand Street, Shiraz, Iran. attarar@sums.ac.ir.ORCID 0000-0002-4133-4870
Fateme Bahmanzadegan JahromiStudents' Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Shahin KavousiStudents' Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Ahmad MonabatiHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Asma KazemiNutrition Research Center, Shiraz University of Medical Sciences, PO Box 71645-111, Shiraz, Iran. Kazemiasma66@gmail.com.
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTrials investigating the role of mesenchymal stem cells (MSCs) in increasing ejection fraction (LVEF) after acute myocardial infarction (AMI) have raised some controversies. This study was conducted to find whether transplantation of MSCs after AMI can help improve myocardial performance indices or clinical outcomes.

methodsRandomized trials which evaluated transplantation of MSCs after AMI were enrolled. The primary outcome was LVEF change. We also assessed the role of cell origin, cell number, transplantation time interval after AMI, and route of cell delivery on the primary outcome.

resultsThirteen trials including 956 patients (468 and 488 in the intervention and control arms) were enrolled. After excluding the biased data, LVEF was significantly increased compared to the baseline among those who received MSC (WMD = 3.78%, 95% CI: 2.14 to 5.42, p < 0.001, I

conclusionTransplantation of MSCs after AMI significantly increases LVEF, showing a higher efficacy if done in the first week. Further clinical studies should be conducted to investigate long-term clinical outcomes such as heart failure and cardiovascular mortality.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationMyocardial InfarctionHumansStroke VolumeVentricular Function, LeftMesenchymalMeta-analysisMyocardial infarctionStem cell

Identifiers

PMID34876213
PMCPMC8650261
OpenAlexW4200143732

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.